Pliant Therapeutics, Inc. PLRX
Set alert
At close · Oct 30
After hours · Oct 30, 6:44 PM ET
- YTD
- -29.60%
- 1 year
- -47.63%
- Open
- 0.867
- Prev close
- 0.86
- Mkt cap
- 53.18M
- Vol
- 169.52K
- Avg vol
- 399.48K
- EPS
- -1.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.84
- High
- 0.8824
- Forward P/E
- -3.32
- Beta
- 1.09
- Short ratio
- 15.30
- Inst. own
- 111.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 7, 2024
- 50-d avg
- 14.08
- 200-d avg
- 13.14
- 1y target
- 40.18
News
2 days ago globenewswire.com
Pliant Therapeutics Announces Presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of…
-
2 months ago benzinga.com
Pliant Therapeutics Receives Fast Track Designation From FDA For PLN-101095 In Combination With Pembrolizumab For Potential Treatment Of Solid Tumors
Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for PLN-101095, an oral, small molecule, dual selective…
-
2 months ago benzinga.com
Pliant Therapeutics Q2 EPS $(0.36) Misses $(0.34) Estimate
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 49.3 percent increase over losses of…
-
6 months ago benzinga.com
Pliant Therapeutics Announces Dosing Of First Participant In FORTIFY Phase 1b Open-Label Indication Expansion Clinical Trial Of PLN-101095 In Combination With Pembrolizumab, In Patients With ICI-Refractory Advanced Or Metastatic Solid Tumors
Pliant Therapeutics (NASDAQ:PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with…
-
7 months ago benzinga.com
Pliant Therapeutics Presents Data From Phase 1 Trial Of PLN-101095 At AACR Annual Meeting 2026
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from…
-
7 months ago benzinga.com
Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3
Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.
-
7 months ago benzinga.com
Piper Sandler Maintains Overweight on Pliant Therapeutics, Lowers Price Target to $3
Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price target from $4 to $3.
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
-
1 year ago benzinga.com
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During the session on Thursday, 461 stocks hit new 52-week lows.
-
3 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Friday's session saw 169 companies set new 52-week lows.
-
3 years ago benzinga.com
Why First Republic Bank Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket
Gainers Hongli Group Inc. (NASDAQ: HLP) gained 317.8% to $17.55 in pre-market trading. Hongli Group recently announced pricing of $8.25 million initial public offering of 2,062,500 ordinary shares at…
-
3 years ago benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
During Thursday, 849 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 242 companies hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Monday
On Monday, 671 companies achieved new lows for the year.
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Thursday
Before 10 a.m. ET Thursday, 371 stocks hit new 52-week highs.
-
5 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
During Monday's morning trading, 285 companies set new 52-week highs.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
Before 10 a.m. ET on Friday, 30 companies set new 52-week lows.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET Thursday, 132 stocks made new 52-week lows.